Metylfenidat Medical Valley

Methylphenidate Hydrochloride, the active ingredient in Metylfenidat Medical Valley, is a central nervous system stimulant presented as an oral tablet for oral use. It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy in children, adolescents, and adults.

GNH USA supplies Metylfenidat Medical Valley as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, ensuring timely delivery and regulatory compliance.

Methylphenidate Hydrochloride is a central nervous system stimulant used in the management of neurodevelopmental and sleep‑wake disorders. - Attention deficit hyperactivity disorder (ADHD) in children and adolescents: improves attention, reduces hyperactivity and impulsivity. - Attention deficit hyperactivity disorder (ADHD) in adults: enhances concentration and decreases distractibility. - Narcolepsy: lessens excessive daytime sleepiness and cataplexy.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced food intake leading to weight loss. - Headache: mild to moderate cranial pain. - Stomach pain: gastrointestinal discomfort. - Irritability: mood changes and increased agitation.

Serious or Rare Side Effects: - Cardiovascular events: hypertension, tachycardia, or arrhythmia. - Psychosis or severe agitation: emergence of hallucinations or delusional thinking. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Priapism: prolonged, painful erection. - Seizures: occurrence of convulsive episodes.

Before initiating therapy, clinicians should consider several safety aspects. - Assess cardiovascular status: evaluate blood pressure and heart rate. - Monitor growth in children: track height and weight regularly. - Avoid use in patients with known hypersensitivity to methylphenidate. - Caution in patients with psychiatric disorders: watch for emergence of psychosis or mania. - Avoid concomitant MAO inhibitors: discontinue MAOI at least 14 days before starting. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture.

Methylphenidate may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: increased risk of cardiovascular side effects. - Antihypertensive agents: may reduce antihypertensive efficacy.

Moderate Interactions (Monitor Closely): - Other CNS stimulants: additive sympathomimetic effects. - Antidepressants (SSRIs, SNRIs): may increase risk of serotonin syndrome. - Anticonvulsants: may alter methylphenidate plasma levels.